Market Summary
USD4.15-0.29
Market Closed-6.53%
STOK Stock Price
STOK RSI Chart
STOK Valuation
STOK Price/Sales (Trailing)
STOK Profitability
STOK Fundamentals
STOK Revenue
STOK Earnings
Price Action
52 Week Range
16.48
(Low)(High)
Last 7 days
-10.7%
Last 30 days
-20.4%
Last 90 days
-66.2%
Trailing 12 Months
-70.9%
STOK Financial Health
STOK Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for STOK
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-03 | Ticho Barry | sold | -158,973 | 10.5982 | -15,000 | chief medical officer |
2023-06-21 | Allan Jonathan | sold | -26,252 | 13.4765 | -1,948 | general counsel & corp sec |
2023-06-01 | Ticho Barry | sold | -166,964 | 11.1309 | -15,000 | chief medical officer |
2023-05-04 | Ticho Barry | sold | -6,530 | 10.00 | -653 | chief medical officer |
2023-05-03 | Ticho Barry | sold | -250,366 | 10.1375 | -24,697 | chief medical officer |
2023-05-02 | Ticho Barry | sold | -55,133 | 10.0007 | -5,513 | chief medical officer |
2023-05-01 | Ticho Barry | sold | -249,767 | 10.0039 | -24,967 | chief medical officer |
2023-03-27 | Kaye Edward M. MD | acquired | 12,000 | 0.6 | 20,000 | ceo |
2023-02-06 | Ticho Barry | sold | -92,491 | 10.0153 | -9,235 | chief medical officer |
2023-02-03 | Ticho Barry | sold | -37,745 | 10.0306 | -3,763 | chief medical officer |
Which funds bought or sold STOK recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -1.89 | 33,381 | 165,828 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -68.45 | -1,578 | 1,062 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 20.29 | 98,791 | 283,417 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 13.5 | 209,355 | 676,355 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 163 | 78,444 | 111,689 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 18.74 | 149,348 | 439,232 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 13.79 | 309,424 | 993,916 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 48.84 | 14,000 | 29,000 | -% |
2023-08-14 | STATE OF WISCONSIN INVESTMENT BOARD | added | 27.39 | 355,375 | 923,439 | -% |
2023-08-14 | GILDER GAGNON HOWE & CO LLC | reduced | -1.66 | 110,282 | 542,917 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Stoke Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | rtw investments, lp | 9.8% | 3,870,981 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 4.06% | 1,602,045 | SC 13G/A | |
| Feb 03, 2023 | redmile group, llc | 9.7% | 4,166,975 | SC 13G/A | |
| Jan 25, 2023 | cowen financial products llc | 1.89% | 1,248,077 | SC 13G/A | |
| Feb 14, 2022 | rtw investments, lp | 9.9% | 3,644,248 | SC 13G/A | |
| Feb 14, 2022 | redmile group, llc | 6.1% | 2,246,668 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Jan 24, 2022 | cowen financial products llc | 5.09% | 1,871,529 | SC 13G | |
| Jun 30, 2021 | skorpios trust | - | 6,905,121 | SC 13D |
Recent SEC filings of Stoke Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 20, 2023 | 3 | Insider Trading | |
| Sep 20, 2023 | 4 | Insider Trading | |
| Sep 20, 2023 | 8-K | Current Report | |
| Sep 18, 2023 | PRE 14A | PRE 14A | |
| Sep 08, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 10-Q | Quarterly Report | |
| Aug 07, 2023 | 8-K | Current Report | |
| Jul 25, 2023 | 8-K | Current Report | |
| Jul 06, 2023 | 4 | Insider Trading | |
| Jun 23, 2023 | 4 | Insider Trading |
Peers (Alternatives to Stoke Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.1B | 56.0B | 2.30% | 9.45% | 31.22 | 4.84 | -2.31% | -31.27% |
BGNE | 258.4B | 1.8B | -1.67% | 25.43% | -149.17 | 142.72 | 69.45% | 14.65% |
VRTX | 91.3B | 9.5B | 0.45% | 22.78% | 27.14 | 9.61 | 13.83% | 5.33% |
REGN | 88.1B | 12.7B | -1.51% | 18.09% | 20.49 | 6.95 | -10.94% | -24.40% |
ALNY | 21.7B | 1.2B | -7.00% | -17.21% | -20.42 | 17.55 | 39.94% | -8.44% |
SRPT | 11.2B | 1.0B | 3.70% | 3.57% | -12.29 | 11.11 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.04 | 4.97 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | 0.04% | -28.00% | -5.4 | 13.27 | -2.11% | 21.02% |
MDGL | 2.9B | - | -10.01% | 147.80% | -8.93 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.63 | 6.49 | 20.50% | -42.46% |
MRTX | 2.1B | 27.2M | -14.18% | -57.07% | -2.89 | 78.22 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.18 | 4.26 | 77.72% | 112.02% |
MGNX | 289.9M | 152.5M | -11.67% | 38.41% | 38.91 | 1.9 | 127.84% | 103.41% |
CRBP | 28.7M | - | 1.35% | 3552.08% | -0.62 | - | - | -31.51% |
Stoke Therapeutics News
Returns for STOK
Cumulative Returns on STOK
-50.9%
3-Year Cumulative Returns
Risks for STOK
What is the probability of a big loss on STOK?
94.6%
Probability that Stoke Therapeutics stock will be more than 20% underwater in next one year
87.5%
Probability that Stoke Therapeutics stock will be more than 30% underwater in next one year.
80.4%
Probability that Stoke Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does STOK drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Stoke Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Stoke Therapeutics
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | ||||||
|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | -100.0% | - | 15.00 | 12.00 | 12.00 | 12.00 | 12.00 |
| Operating Expenses | 1.9% | 121 | 119 | 117 | 111 | 103 | 97.00 |
| S&GA Expenses | 0.3% | 40.00 | 40.00 | 39.00 | 38.00 | 37.00 | 34.00 |
| R&D Expenses | 2.8% | 81.00 | 79.00 | 78.00 | 73.00 | 67.00 | 63.00 |
| Net Income | -6.1% | -104 | -98.96 | -101 | -99.86 | -96.35 | -93.66 |
| Net Income Margin | 100.0% | - | -6.80* | -8.15* | -8.20* | -7.73* | -7.81* |
| Free Cashflow | 100.0% | - | -89.00 | -35.83 | -29.51 | -20.38 | -16.12 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
| Assets | -8.8% | 257 | 282 | 256 | 278 | 301 | 316 | 239 | 254 | 264 | 279 | 298 | 200 | 210 | 221 | 229 | 239 | 246 | 108 |
| Current Assets | -8.9% | 246 | 270 | 244 | 265 | 289 | 306 | 229 | 245 | 260 | 275 | 294 | 195 | 206 | 216 | 226 | 237 | 244 | 106 |
| Cash Equivalents | 0.9% | 192 | 190 | 114 | 113 | 68.00 | 84.00 | 145 | 149 | 169 | 268 | 287 | 191 | 202 | 211 | 222 | 233 | 243 | 105 |
| Net PPE | -4.7% | 6.00 | 7.00 | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 |
| Liabilities | -1.8% | 67.00 | 68.00 | 71.00 | 73.00 | 77.00 | 76.00 | 21.00 | 16.00 | 9.00 | 6.00 | 12.00 | 7.00 | 7.00 | 6.00 | 4.00 | 5.00 | 5.00 | 2.00 |
| Current Liabilities | -30.7% | 22.00 | 32.00 | 31.00 | 29.00 | 28.00 | 23.00 | 17.00 | 12.00 | 8.00 | 6.00 | 11.00 | 7.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 2.00 |
| Shareholder's Equity | -11.0% | 190 | 214 | 185 | 204 | 224 | 240 | 218 | 238 | 255 | 272 | 286 | 193 | 203 | 214 | 224 | 234 | 242 | 105 |
| Retained Earnings | -9.6% | -350 | -319 | -297 | -271 | -245 | -220 | -196 | -171 | -149 | -127 | -110 | -95.72 | -82.03 | -69.07 | -58.03 | -47.87 | -39.27 | -25.71 |
| Additional Paid-In Capital | 1.3% | 541 | 534 | 483 | 477 | 471 | 461 | 414 | 409 | 404 | 400 | 396 | 288 | 285 | 283 | 282 | 282 | 281 | 131 |
| Shares Outstanding | 0.1% | 44.00 | 44.00 | 39.00 | 39.00 | 39.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 33.00 | 33.00 | 33.00 | 33.00 | 13.00 | 3.00 | 1.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -2.2% | -87,585 | -85,713 | -31,866 | -25,751 | -18,377 | -14,280 | -66,907 | -61,580 | -57,771 | -51,586 | -42,221 | -41,491 | -38,666 | -35,294 | -31,055 | -24,369 | -19,362 | -17,450 | -10,964 | -12,164 | -8,816 |
| Share Based Compensation | 2.5% | 24,363 | 23,766 | 22,854 | 21,750 | 20,438 | 18,727 | 16,450 | 13,344 | 10,515 | 7,712 | 5,768 | 4,900 | 3,846 | 2,495 | 1,922 | 1,329 | 638 | 453 | 240 | 160 | 162 |
| Cashflow From Investing | 16.3% | 166,312 | 142,985 | -45,882 | -56,575 | -129,103 | -212,004 | -76,426 | -88,313 | -83,318 | -644 | -1,050 | -1,529 | -1,843 | -2,154 | -1,634 | -1,148 | -1,081 | -918 | -925 | -2,064 | -652 |
| Cashflow From Financing | -6.9% | 45,579 | 48,956 | 46,409 | 46,537 | 46,511 | 43,245 | 1,284 | 107,981 | 108,246 | 108,456 | 108,108 | 1,432 | -241 | 150,028 | 149,762 | 239,349 | 253,727 | 137,452 | 115,639 | 53,512 | 24,964 |
STOK Income Statement
2023-06-30Consolidated statements of operations and comprehensive loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenue | $ (2,481) | $ 3,231 | $ 2,671 | $ 6,232 |
| Operating expenses: | ||||
| Research and development | 20,551 | 18,358 | 40,182 | 36,668 |
| General and administrative | 10,230 | 10,111 | 20,442 | 19,596 |
| Total operating expenses | 30,781 | 28,469 | 60,624 | 56,264 |
| Loss from operations | (33,262) | (25,238) | (57,953) | (50,032) |
| Other income: | ||||
| Interest income (expense), net | 2,567 | 544 | 4,670 | 648 |
| Other income (expense), net | 41 | 42 | 84 | 83 |
| Total other income | 2,608 | 586 | 4,754 | 731 |
| Net loss | $ (30,654) | $ (24,652) | $ (53,199) | $ (49,301) |
| Net loss per share, basic | $ (0.69) | $ (0.63) | $ (1.23) | $ (1.29) |
| Net loss per share, diluted | $ (0.69) | $ (0.63) | $ (1.23) | $ (1.29) |
| Weighted-average common shares outstanding, basic | 44,188,464 | 39,258,358 | 43,367,032 | 38,358,936 |
| Weighted-average common shares outstanding, diluted | 44,188,464 | 39,258,358 | 43,367,032 | 38,358,936 |
| Comprehensive loss: | ||||
| Net loss | $ (30,654) | $ (24,652) | $ (53,199) | $ (49,301) |
| Other comprehensive gain (loss): | ||||
| Unrealized gain (loss) on marketable securities | 219 | (592) | 796 | (1,108) |
| Total other comprehensive loss | 219 | (592) | 796 | (1,108) |
| Comprehensive loss | $ (30,435) | $ (25,244) | $ (52,403) | $ (50,409) |
STOK Balance Sheet
2023-06-30Consolidated balance sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 192,060 | $ 113,556 |
| Marketable securities | 39,387 | 116,039 |
| Prepaid expenses | 10,950 | 10,932 |
| Other current assets | 3,699 | 2,955 |
| Interest receivable | 136 | 588 |
| Total current assets | 246,232 | 244,070 |
| Restricted cash | 569 | 569 |
| Operating lease right-of-use assets | 3,646 | 4,753 |
| Property and equipment, net | 6,472 | 6,675 |
| Total assets | 256,919 | 256,067 |
| Current liabilities: | ||
| Accounts payable | 1,556 | 766 |
| Accrued and other current liabilities | 12,222 | 15,748 |
| Deferred revenue - current portion | 8,059 | 14,880 |
| Total current liabilities | 21,837 | 31,394 |
| Deferred revenue - net of current portion | 43,258 | 36,856 |
| Other long term liabilities | 1,629 | 2,968 |
| Total long term liabilities | 44,887 | 39,824 |
| Total liabilities | 66,724 | 71,218 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 44,202,997 and 39,439,575 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 4 | 4 |
| Additional paid-in capital | 540,919 | 483,170 |
| Accumulated other comprehensive loss | (379) | (1,175) |
| Accumulated deficit | (350,349) | (297,150) |
| Total stockholders’ equity | 190,195 | 184,849 |
| Total liabilities and stockholders’ equity | $ 256,919 | $ 256,067 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.